ClinicalTrials.gg
Not yet recruitingNCT07681154PEUpdated Nov 20, 2026

Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism

An interventional study of Thrombolysis Catheter in Pulmonary Embolism (PE) and Pulmonary Embolism With Right Ventricle Enlargement, sponsored by Flow Medical Solutions, Inc.. Not yet recruiting at 1 site in Chile. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Flow Medical Solutions, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026First site in ChileStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a pilot study of the Flow Medical Catheter, a catheter-based device used to deliver clot-dissolving medication directly to a blood clot in the lungs (pulmonary embolism). The study evaluates whether the device can be used safely and as intended in adults with intermediate-risk acute pulmonary embolism. All participants receive treatment with the study device; there is no comparison group.

Read the detailed description

This single-arm, pilot study evaluates the safety and feasibility of the Flow Medical Catheter for catheter-directed thrombolysis in adults with acute intermediate-risk pulmonary embolism. Participants undergo the catheter-directed thrombolysis procedure with the study device and are followed for procedure-related safety outcomes during the early post-procedure period. Eligibility criteria, study intervention, and outcome measures are described in the corresponding structured sections of this record.

The study may enroll up to a maximum of 20 participants, with periodic safety reviews conducted throughout enrollment.

02

Conditions studied

  • Pulmonary Embolism (PE)
  • Pulmonary Embolism With Right Ventricle Enlargement

Browse trials for

Keywords

  • catheter directed thrombolysis, lysis, lytics, thrombolysis
03

In context

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

This study's planned enrollment of 20 is below the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.

Browse Pulmonary Embolism studies →

Lead sponsor

This is the only study on the registry with Flow Medical Solutions, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet ALL of the following criteria to be eligible:

  1. Age 18 to 75 years, inclusive.
  2. Clinical signs and/or symptoms consistent with acute PE with symptom onset ≤14 days prior to baseline CTPA.
  3. CTPA demonstrating acute PE with a filling defect in at least one main or lobar pulmonary artery.
  4. RV/LV diameter ratio ≥0.9 on baseline CTPA (site read acceptable for eligibility determination).
  5. Medically eligible for CDT and standard anticoagulation per institutional guidelines and the treating investigator's judgment.
  6. Willing and able to provide written and comply with all study procedures and follow-up requirements.

Exclusion criteria

Exclusion Criteria:

Subjects meeting ANY of the following criteria are not eligible:

  1. High-risk (massive) PE: Sustained SBP \<90 mmHg for ≥15 consecutive minutes, >40 mmHg drop from baseline, vasopressor requirement, or cardiac arrest requiring cardiopulmonary resuscitation during the immediate hospitalization.
  2. Respiratory insufficiency: FiO₂ requirement >40% or >6 LPM supplemental oxygen to maintain SpO₂ >90%.
  3. Prior PE: Prior PE ≤180 days from index procedure.
  4. Absolute to thrombolytic therapy:

    1. Any prior intracranial hemorrhage (no time limit)
    2. Known structural cerebrovascular lesion or arteriovenous malformation (no time limit)
    3. Known malignant intracranial neoplasm (no time limit)
    4. Ischemic stroke or within 3 months of baseline CTPA
    5. Intracranial or intraspinal surgery within 2 months of baseline CTPA
    6. Significant closed-head or facial trauma within 3 months of baseline CTPA
    7. Suspected aortic dissection
    8. Active bleeding or bleeding diathesis (excluding menses)
    9. Active intracranial or intraspinal disease
    10. Irreversible neurological compromise
  5. Relative contraindications to thrombolytic therapy:

    1. Severe uncontrolled hypertension at presentation (SBP >180 mmHg or DBP >110 mmHg)
    2. Major surgery within 3 weeks of baseline CTPA
    3. Major trauma (non-intracranial) within 3 months of baseline CTPA
    4. Traumatic or prolonged CPR (>10 minutes) within 3 weeks of baseline CTPA
    5. Recent internal bleeding within 4 weeks of baseline CTPA
    6. Noncompressible vascular puncture site(s)
    7. Active peptic ulcer
    8. Ischemic stroke more than 3 months prior to baseline CTPA
  6. Laboratory exclusions (within 6 hours of index procedure, not correctable prior to procedure):

    1. count \<100,000/µL
    2. \<8.0 g/dL
    3. >2.0; or INR >1.5 if currently receiving warfarin
    4. aPTT >50 seconds in the absence of anticoagulant therapy
    5. \<30 mL/min/1.73 m²
  7. Cardiac and pulmonary exclusions:

    1. Known ≤30% by any imaging modality
    2. Decompensated heart failure at presentation requiring inotropic or diuretic escalation unrelated to the index PE event
    3. History of chronic lung disease requiring supplemental oxygen therapy at baseline
    4. Known chronic severe pulmonary hypertension not attributable to the index PE episode (documented PASP >70 mmHg by right heart catheterization or echocardiography, or documented CTEPH)
    5. Profound bradycardia requiring temporary pacing or inotropic support
  8. Procedural and anatomical exclusions:

    1. Known or suspected clot in transit (right atrium or right ventricle), IVC clot, or intracardiac thrombus
    2. Intracardiac lead in the right ventricle or right atrium placed ≤180 days prior to the index procedure
    3. Actively progressing cancer treated with chemotherapy
    4. Anatomic or clinical conditions precluding safe venous access or catheter delivery to the pulmonary arteries
    5. >45 kg/m² if, in the judgment of the investigator, body habitus poses unacceptable risk for vascular access, catheter delivery, or procedural bleeding management
  9. Device and drug :

    1. Allergy or hypersensitivity to rt-PA (alteplase)
    2. Heparin allergy or history of heparin-induced thrombocytopenia (HIT)
    3. Known hypersensitivity to nitinol (nickel-titanium alloy)
    4. Known anaphylactic reaction to radiographic contrast agents not amenable to premedication
  10. Prior thrombolytic use or glycoprotein IIb/IIIa inhibitor use within 3 days of baseline CTPA.
  11. Use of a direct oral anticoagulant (DOAC) within 48 hours of the index procedure, unless the investigator judges procedural bleeding risk to be acceptable and documents this determination, with rationale, in the subject's medical record.
  12. Pregnancy. A pregnancy test is required for all women of prior to enrollment; point-of-care testing is acceptable. Patients with a positive pregnancy test are excluded. Postpartum patients are eligible if all other criteria are met.
  13. \<90 days in the investigator's judgment.
  14. Concurrent enrollment in another interventional clinical investigation.
  15. Previous enrollment in this study.
  16. Absolute contraindication to anticoagulation, or inability to receive post-procedure anticoagulation per institutional standard of care.
  17. Unable or unwilling to provide written .
  18. Any other clinical, anatomical, or procedural condition not otherwise specified in the exclusion criteria that, in the investigator's expert clinical judgment, would place the subject at unacceptable risk of major bleeding, vascular injury, unsafe venous or pulmonary artery access or catheter delivery, or another serious procedure- or device-related complication. The specific rationale for exclusion must be documented in the subject's medical record.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Catheter-Directed Thrombolysis (Flow Medical Catheter)

    All participants undergo catheter-directed thrombolysis with the Flow Medical Catheter for treatment of acute intermediate-risk pulmonary embolism. This is a single-arm study; all enrolled participants receive the same study intervention.

    Device: Thrombolysis Catheter

Interventions

  • DeviceThrombolysis Catheter

    Catheter-directed thrombolysis is performed using the Flow Medical Catheter to deliver a thrombolytic agent directly into the pulmonary arteries. The device is positioned at the target site, and thrombolytic infusion is delivered per the study protocol.

    Also known as: PE Catheter, Catheter Directed Thrombolysis

06

What researchers measure

Primary outcomes

  1. Incidence of device-related serious adverse events (SAEs)

    Number of participants experiencing one or more serious adverse events assessed as related to the study device.

    Time frame: 72 hours post procedure

  2. Successful device deployment and thrombolytic infusion

    Proportion of participants in whom the Flow Medical scaffold is successfully deployed and expanded within the target pulmonary artery, with confirmed initiation and maintenance of thrombolytic infusion through the device for the protocol-specified duration.

    Time frame: Index Procedure through 24 hours post

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Of 150 interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 6 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Chile
Show site
  • Hospital Regional de Talca (HRT) · Talca, Chile
Nov 6, 2026
Start date
Oct 2026→Nov 2026
Nov 6, 2026
Eligibility
2 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Exclusion criteria
  • EditedDecompensated heart failure at presentation requiring inotropic or diuretic escalation unrelated to the index PE procedureevent
  • EditedActively progressing cancer actively treated with chemotherapy
  • RemovedIn the opinion of the investigator, the subject is at unacceptably high risk for bleeding complications or is otherwise not a suitable candidate for the study
  • AddedAny other clinical, anatomical, or procedural condition not otherwise specified in the exclusion criteria that, in the investigator's expert clinical judgment, would place the subject at unacceptable risk of major bleeding, vascular injury, unsafe venous or pulmonary artery access or catheter delivery, or another serious procedure- or device-related complication. The specific rationale for exclusion must be documented in the subject's medical record.
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added — first site in Chile
    Show site
    • Hospital Regional de Talca (HRT) · Talca, Chile
    Start date Oct 2026→Nov 2026
    Eligibility 2 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • EditedDecompensated heart failure at presentation requiring inotropic or diuretic escalation unrelated to the index PE procedureevent
    • EditedActively progressing cancer actively treated with chemotherapy
    • RemovedIn the opinion of the investigator, the subject is at unacceptably high risk for bleeding complications or is otherwise not a suitable candidate for the study
    • AddedAny other clinical, anatomical, or procedural condition not otherwise specified in the exclusion criteria that, in the investigator's expert clinical judgment, would place the subject at unacceptable risk of major bleeding, vascular injury, unsafe venous or pulmonary artery access or catheter delivery, or another serious procedure- or device-related complication. The specific rationale for exclusion must be documented in the subject's medical record.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07681154
Lead sponsor
Flow Medical Solutions, Inc.
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Bryan Wylie
Contact
clinical@flowmedical.co
+1 650 224 5810
Miguel Naranjo, MD
principal investigator · Hospital Regional de Talca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion